23andMe Receives Court Approval for Asset Sale to TTAM Research Institute, Ensuring Continued Focus on Genomic Understanding
Reuters
Jun 30
23andMe Receives Court Approval for Asset Sale to TTAM Research Institute, Ensuring Continued Focus on Genomic Understanding
I don't have information on any new grant or regulatory approval announced by 23andMe Holding Co. beyond the sale of its assets to TTAM Research Institute, as approved by the U.S. Bankruptcy Court for the Eastern District of Missouri. If there are recent developments regarding grants or regulatory approvals, I am not aware of them.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 23Andme Holding Co. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-152020), on June 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.